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Abstract: Monoclonal antibodies are conquering the biopharmaceutical market because they can be used
to treat a variety of diseases. Therefore, it is very important to establish robust and optimized processes
for their production. In this article, the first step of chromatography (Protein A chromatography)
in monoclonal antibody purification was optimized with a focus on the critical elution step.
Therefore, different buffers (citrate, glycine, acetate) were tested for chromatographic performance and
product quality. Membrane chromatography was evaluated because it promises high throughputs
and short cycle times. The membrane adsorber Sartobind® Protein A 2 mL was used to accelerate
the purification procedure and was further used to perform a continuous chromatographic run with
a four-membrane adsorber-periodic counter-current chromatography (4MA-PCCC) system. It was
found that citrate buffer at pH 3.5 and 0.15 M NaCl enabled the highest recovery of >95% and lowest
total aggregate content of 0.26%. In the continuous process, the capacity utilization of the membrane
adsorber was increased by 20%.
Keywords: monoclonal antibody; membrane adsorber; protein A chromatography; periodic
counter-current chromatography
1. Introduction
Monoclonal antibodies (mAb) “deliver considerable medical benefits” [1]. This is reflected in the
increase in the number of available drugs based on monoclonal antibodies. In 2016, seven mAbs were
approved in the US or EU and by the end of 2018, a further 12 mAbs had been approved in the US or
EU for the treatment of e.g., cancer, transplant patients, autoimmune diseases and others [2,3].
Antibodies are a central component of the human immune system and are produced by activated
B-cells as an immune response to the intrusion of antigens. They belong to the immunoglobulin
family and are divided into five immunoglobulin classes (IgG, IgA, IgM, IgD and IgE), which are also
subdivided into subgroups (e.g., IgG1, IgG2, IgG3, IgG4). Antibodies are glycoproteins and consist of
four polypeptide chains, two heavy chains (50–60 kDa) and two light chains (23–25 kDa). The two
identical heavy chains are connected by two disulfide bridges and each is linked by a disulfide bridge
to one of the light chains. The light chains (LC) and heavy chains (HC) have a variable region (V-region)
at one end that serves as a binding site for the antigen [4–6]. Monoclonal antibodies bind specifically to
a defined epitope of an antigen and thus trigger the immune defense system; this has attracted interest
in their medicinal applications [4]. The application of monoclonal antibodies in human medicine
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ranges from the treatment of allergies, asthma, multiple sclerosis, in the fight against various types of
cancer and to their use in transplant patients [7–9].
The production process for monoclonal antibodies is divided into production (upstream processing)
and purification (downstream processing). The efficiency of the upstream process has increased
significantly over the past few decades. The hybridoma technique has provided the basis for the
targeted and reproducible amplification of monoclonal antibodies, so that now it is possible to produce
monoclonal antibodies in recombinant cells on a large scale [6,7,10]. Production is often performed in
Chinese Hamster Ovary (CHO) cells, whereby the monoclonal antibody is correctly glycosylated and
secreted into the medium. Not only is the cultivation crucial for the production, but the following
steps in the process must also be carefully considered. Subsequent downstream processing (DSP)
must be of a high standard to meet all regulatory requirements and ensure clinical efficacy [11].
With increasing product titers in cultivation, the upstream processing (USP) costs do not increase
significantly, while process costs in downstream processing increase in proportion to the quantity of
the product to be purified. Therefore, with improved production, production costs shift to the DSP
and can account for 50–80% [12] of total process costs [13–16]. DSP can be divided into a number of
steps (shown in Figure 1), which should lead to a highly purified and effective drug.
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After cultivation, the cells are separated from the supernatant (by e.g., centrifugation or depth 
filtration [17]); this is the last operation in the USP. Obtaining the clarified supernatant legally divides 
the entire process into the cell-containing process steps (USP) and the subsequent cell-free process 
steps (DSP). The first step in the chromatography is the capture step using Protein A chromatography 
in combination with virus inactivation. In this step, the monoclonal antibody should be isolated and 
concentrated from the supernatant, and the contaminants or impurities (DNA, host cell proteins and 
cell culture medium components) should be eliminated. The polishing steps (e.g., cation exchange 
chromatography, hydrophobic interaction chromatography, anion exchange chromatography) are 
then performed to remove the last impurities and achieve the final purity of the product. 
Ultrafiltration and diafiltration are used to obtain suitable buffer and formulation conditions [18,19]. 
These steps should be optimized in order to reduce the process costs for downstream processing. 
The most expensive step is the Protein A chromatography step; thus it offers a good starting point. 
This affinity chromatography method is based on the interaction of the monoclonal antibody with 
immobilized Protein A. The binding is primarily formed by hydrophobic interactions, but also 
hydrogen bonds and ionic interactions have an influence on the interaction [20,21]. The Protein A 
ligand was originally derived from the bacterium Staphylococcus aureus and serves as a binding site 
for IgG class antibodies in the cell wall. Protein A binds the antibody at the fragment crystallizable 
(Fc) region of the heavy chain [20,22,23]. Depending on the subclass of the antibody, the binding 
between the antibody and Protein A takes place in a pH range of 6–9 and can be influenced by the 
salt concentration in the binding buffer [5,20,24]. To release the binding, an elution buffer with a low 
pH between pH 2.5 and pH 4.5 is selected, taking into account that a low pH may affect the 
functionality and stability of the antibody and it may also support aggregate formation, which can 
lead to problems in further processing or in drug safety [18,20,22,25,26]. Since the elution of the 
antibody takes place at a low pH value, this is also used for virus inactivation. The eluate should be 
incubated for 30–120 min at a pH value lower than pH 3.8 in order to inactivate retroviruses [22,27]. 
The selection of a suitable elution buffer and the parameters for elution is particularly important 
for effective Protein A chromatography and good product quality. The elution can be optimized by 
Figure 1. Process steps in the downstream processing of a monoclonal antibody (summarized and
modified from [12]).
After cultivation, the cells are separated from the supernatant (by e.g., centrifugation or depth
filtration [17]); this is the last operation in the USP. Obtaining the clarified supernatant legally divides
the entire process into the cell-containing process steps (USP) and the subsequent cell-free process
steps (DSP). The first step in the chromatography is the capture step using Protein A chromatography
in combination with virus inactivation. In this step, the monoclonal antibody should be isolated and
concentrated from the supernatant, and the contaminants or impurities (DNA, host cell proteins and
cell culture medium components) should be eliminated. The polishing steps (e.g., cation exchange
chromatography, hydrophobic interaction chromatography, anion exchange chromatography) are then
performed to remove the last impurities and achieve the final purity of the product. Ultrafiltration and
diafiltration are used to obtain suitable buffer and formulation conditions [18,19].
These steps should be optimized in order to reduce the process costs for downstream processing.
The most expensive step is the Protein A chromatography step; thus it offers a good starting point.
This affinity chromatography method is based on the interaction of the monoclonal antibody with
immobilized Protein A. The binding is primarily formed by hydrophobic interactions, but also hydrogen
bonds and ionic interactions have an influence on the interaction [20,21]. The Protein A ligand was
originally derived from the bacterium Staphylococcus aureus and serves as a binding site for IgG class
antibodies in the cell wall. Protein A binds the antibody at the fragment crystallizable (Fc) region of the
heavy chain [20,22,23]. Depending on the subclass of the antibody, the binding between the antibody
and Protein A takes place in a pH range of 6–9 and can be influenced by the salt concentration in
the binding buffer [5,20,24]. To release the binding, an elution buffer with a low pH between pH 2.5
and pH 4.5 is selected, taking into account that a low pH may affect the functionality and stability
of the antibody and it may also support aggregate formation, which can lead to problems in further
processing or in drug safety [18,20,22,25,26]. Since the elution of the antibody takes place at a low
pH value, this is also used for virus inactivation. The eluate should be incubated for 30–120 min
at a pH value lower than pH 3.8 in order to inactivate retroviruses [22,27].
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The selection of a suitable elution buffer and the parameters for elution is particularly important
for effective Protein A chromatography and good product quality. The elution can be optimized by
additives [20,28,29] or the use of salts to prevent e.g., ionic interaction and thus increase the pH value
during elution [20,24]. The addition of small amounts of salt can also have a positive effect on the
stability of the antibody. Different buffer systems have already been tested for the purification of IgG1
antibodies with Protein A chromatography (citrate and acetate buffer) [30–32], whereas Müller and
Vajda [32] observed better results with acetate buffer in regard to recovery. All authors observed that
increasing pH had a negative effect on the recovery of the mAb. At pH 2.8–3.3, the recovery rate was
higher than 90% whereas at pH 3.8 the recovery rate decreased to under 50%. Salt showed a negative
effect on the elution in the work of Gagnon et al. [30]. Further, elution buffers were tested in regard to
aggregate formation [32,33]: in the concentration range from 0–1.5 M NaCl, a negative effect of salt was
observed and aggregation was induced while the pH value of the buffer also influenced the aggregate
formation. Müller and Vajda [32] found about 1% aggregate in the range of pH 3–4. Singla et al. [34]
investigated the aggregation kinetics, taking into account the pH, temperature, salt concentration
(NaCl) and buffer species. They evaluated citrate, glycine and acetate buffer at pH 3.0 and found that
these factors influenced aggregation in the following order with decreasing effect: pH, temperature,
salt concentration and buffer species. At pH 3.0, citrate buffer induced the highest aggregation even
without the addition of salt.
To address the issue that the process costs increase proportionally with the product titers in
downstream processing, new optimization approaches were considered in this paper. One alternative
is the use of other stationary phases such as disposable membrane adsorbers. They offer several
advantages over conventional columns, e.g., higher throughputs and therefore shorter cycle times,
an increase in productivity as well as easy up- and downscale of production, especially in the
purification of low-concentrate products [35–39]. Some application examples of mAb purification with
membrane adsorbers are summarized in Table 1.
Table 1. Application examples of membrane chromatography for monoclonal antibody (mAb) purification.
Field of Application Ref.
Affinity chromatography [40]
Ion exchange chromatography [40–43]
Hydrophobic interaction chromatography [41,42]
Accelerated, Seamless Antibody Purification (ASAP)-continuous method
(Protein A chromatography, cation and anion exchange chromatography) [44]
In addition, continuous chromatography processes promise a further increase in productivity [45]
and are therefore increasingly used in mAb processing [46,47]. It has been shown that continuous
chromatography overcomes the problems of batch chromatography, whereby the capacity utilization
of the stationary phase is significantly increased. This reduces the required amount of stationary phase,
and hence reduces the material costs in DSP. This is especially interesting for the costly Protein A
chromatography step in mAb purification.
In this study, Protein A chromatography was performed with a design of experiments (DoE) based
approach to optimize the critical elution step for mAb purification. Membrane adsorbers were utilized
to evaluate the potential of alternatives to conventional column chromatography and to accelerate the
purification process. The implementation of continuous membrane chromatography was performed to
further increase the productivity of the process and to evaluate the use of continuous chromatography
with membrane adsorbers.
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2. Materials and Methods
2.1. Materials
In this study a monoclonal antibody of the IgG1-type was used, which was produced with
CHO cells in a serum-free medium. The antibody has a molecular weight of 148 kDa and a pI
(isoelectric point) value at pH 8.25.
All chemicals were bought from Carl-Roth (Karlsruhe, Germany).
2.2. Methods
2.2.1. Cell Separation with Depth Filtration
The monoclonal antibody was produced in CHO cells and secreted into the cell culture medium.
Since the antibody must be purified for later use, the cells and cell debris were first removed
from the culture supernatant. For this first step, two-stage depth filtration (first step: Sartoclear®
DL90, Göttingen, Germany; second step: Sartoclear® DL20, Göttingen, Germany) was performed.
The clarified material contained 1.9 g/L monoclonal antibody.
2.2.2. Purification of the Monoclonal Antibody
The development of the Protein A chromatography method was performed using the Sartobind®
Protein A 2 mL membrane adsorber from Sartorius Stedim Biotech (Göttingen, Germany) and the
ÄKTA™ pure system with a fraction collector from GE Healthcare (Uppsala, Sweden).
A chromatography run consisted of different phases. First the membrane adsorber was equilibrated
with buffer A (phosphate-buffered saline (PBS) buffer, pH 7.4), then the clarified supernatant was
applied on to the membrane adsorber and all unbound substances were removed by a washing step
with buffer A. Elution with buffer B (see Table 2) was then followed by a cleaning in place (CIP) step
and regeneration of the membrane adsorber. The buffers were connected to the ÄKTA inlets as follows:
Inlet A1: buffer A, Inlet A2: CIP buffer (50 mM NaOH, 1 M NaCl). The sample was introduced
via the sample loop (maximum sample volume 10 mL), and the various elution buffers (buffer B)
from the design of experiments (DoE) in Table 2 were connected via inlets B1 to B5. In this study,
three buffers systems for the monoclonal antibody elution were tested: 0.1 M citrate buffer (pH 2.5–4
and 0–0.5 M NaCl), 0.1 M glycine buffer (pH 2.5–4 and 0–0.5 M NaCl) and 0.1 M acetate buffer (pH 3.5–4
and 0–0.5 M NaCl). In the chromatography experiments, recovery (in %) and peak height (in mAU)
were defined as target parameters. The ÄKTA™ was cooled to 10 ◦C and operated at a flow rate of
5 mL/min during the experiments.
The DoE was performed with a 2-factor design (pH and NaCl concentration), whereas
chromatography performance was evaluated by using the target parameters, peak height and recovery,
and antibody stability was evaluated by the monomeric antibody amount and the aggregate content.
The software, MODDE® (Umetrics, Version 12, Sweden) was used for planning and evaluation of the
experiments. The models were selected according to the suggestions of the software.
2.2.3. Stability Experiments
In order to perform the stability experiments, 19.2 µL of the already purified mAb were pipetted into
0.25 mL of the various elution buffers to be incubated (for 1 h, 24 h and one week at 20 ◦C, 4 ◦C and−20 ◦C).
A SEC-HPLC as described in Section 2.3.1, was then performed. The evaluation stability was investigated
by determining the monomeric antibody amount (in %) and aggregate content (in µV*mL or %).
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2.3. Analytical Methods
2.3.1. SEC-HPLC
Monoclonal antibody, fragment and aggregate concentration was determined using a commercial
HPLC system operated with the column YarraTM 3 µm SEC-3000 (Phenomenex, Torrance, CA, USA).
The samples for the SEC-HPLC were diluted as required, so that a concentration of about 0.5 g/L was
obtained. The samples were then filtered (0.2 µm) and cooled in an autosampler (10 ◦C). The system
was operated with a flow rate of 1 mL/min and a pressure of 112 bar. A total of 5 µL from each sample
was added to the column (oven temperature 25 ◦C) and the measurement was carried out for 20 min.
A combination of 100 mM Na3PO4 buffer and 100 mM Na2SO4 at pH 6.6 was used as the mobile phase.
2.3.2. SDS-PAGE
For qualitative analysis of the monoclonal antibody, SDS-PAGE was carried out using a collecting
gel with 6% acrylamide and a separation gel with 10% acrylamide. The samples were mixed with
Lämmli buffer in the ratio 1:1 and boiled for 10 min at 95 ◦C. To run the gel, 1–10 µl of the sample as well
as 5 µl of the Marker (PageRuler™Unstained Protein Ladder, Thermo Scientific™, Waltham, MA, USA)
were applied. For the separation, a voltage of 100 V was first applied to the loaded gel for 15 min,
then the voltage was increased to 150 V for a further 60 min. For visualization, Coomassie staining [48]
and silver staining [49] was used.
Table 2. Design of experiments (DoE) screening for 0.1 M citrate-, 0,1 M glycine-buffer and 0.1M acetate,
N5–N7 are the center points.
Screening 1 Optimization 2
Citrate/Glycine Buffer Acetate Buffer Citrate Buffer
Exp. Order pH NaCl [M] Exp. Order pH NaCl [M] Exp. Order pH NaCl [M]
N1 1 2.5 0 N1 1 3.5 0 N1 4 3 0
N2 7 4 0 N2 7 4 0 N2 7 3.8 0
N3 2 2.5 0.5 N3 2 3.5 0.5 N3 2 3 0.2
N4 4 4 0.5 N4 4 4 0.5 N4 6 3.8 0.2
N5 5 3.25 0.25 N5 5 3.75 0.25 N5 10 3 0.1
N6 6 3.25 0.25 N6 6 3.75 0.25 N6 1 3.8 0.1
N7 3 3.25 0.25 N7 3 3.75 0.25 N7 3 3.4 0
N8 11 3.4 0.2
N9 5 3.4 0.1
N10 8 3.4 0.1
N11 9 3.4 0.1
1 Full Fac 2 level, interaction model, fitted with: PLS; 2 CCF, quadratic model, fitted with: PLS.
2.3.3. Intrinsic Protein Fluorescence
To study the folding of the monoclonal antibody, the intrinsic protein fluorescence was measured
with Tycho NT.6 (NanoTemper Technologies, Munich, Germany). For the measurement, 10 µL sample
were used. During the measurement, the samples are thermally denatured by a temperature gradient
and the fluorescence is detected. Due to the progressive denaturation, a slow unfolding of the proteins
takes place whereby the amino acids, tryptophan and tyrosine, which fluoresce when excited with UV
light, are increasingly exposed to the medium. As a result, the intrinsic protein fluorescence increases.
A high value of intrinsic fluorescence indicates increased unfolding. For a good evaluation of the
results obtained, they should be compared with a reference in order to evaluate whether the structure
of the sample also corresponds to the desired product. The ratio of light absorption at a wavelength of
350 nm and 330 nm provides information on the quality of the protein [50].
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2.4. Equipment
2.4.1. Membrane Adsorber
For this study the Sartobind® A membrane adsorber was used. The membrane adsorber consists
of 20 layers (4 mm bed height) of stabilized reinforced cellulose (pore size 0.45 µm) and has a nominal
adsorption area of 100 cm2, a bed volume of 2 mL and a ligand density of 1.5 mg/mL recombinant
Protein A. Information was taken from the manufacturer’s user manual and the data sheet for the
membrane adsorber. The dynamic binding capacity was determined as 5.9 mg/mL and the static
binding capacity was 7.5 mg/mL.
2.4.2. Chromatographic System
The commercial system, ÄKTA™ pure (GE Healthcare) was used in this study. For continuous
purification, a self-established chromatographic system with four membrane adsorbers (4MA-PCCC,
Hanover, Germany) was used. The system was first described in [51] for use with three
membrane adsorbers. A fourth chromatography unit with a measurement system was added
to the system to provide more flexibility and functionality, and in particular, the implementation of
the interconnected wash [51–53] to recover more product. The system is equipped with flow-through
cuvettes with a 2 mm pathlength. A calibration curve was recorded with purified mAb and can be
seen in Appendix A, Figure A1.
The continuous run was operated with a feed rate of 1.5 mL/min and a flow rate of 5 mL/min for
buffer A and B. Switching conditions (SC1 and SC2) were set to 10 and 70% product breakthrough [54].
3. Results
3.1. Optimization of Chromatography Buffers
In order to achieve the best purification results, binding and elution buffers were tested and
optimized for the membrane adsorber, Sartobind® Protein A 2 ml. PBS at a neutral pH is often
used as a standard binding buffer. Therefore, PBS binding buffer was tested in the pH range of 6–8
(see Appendix A). Here, no significant difference in chromatography performance was observed, hence
standard PBS with pH 7.4 was chosen for monoclonal antibody binding.
The elution in Protein A chromatography is much more critical as a low pH value may lead to
aggregation and denaturation of the antibody [32,33]. Therefore, the elution buffer was investigated
in more detail. Above all, a compromise must be found between the performance and stability of
the antibody.
3.1.1. Screening of the Elution Buffers with Stability Testing
In the first experimental series, a DoE screening with seven experiments for each buffer variant
was performed (see Table 2). The results are shown in Figure 2 and are a summary of the results of
the chromatography and stability experiments (not all data is shown, see Appendix A, Figure A2 for
citrate buffer results).
A clear trend can be seen in the chromatography experiments. Citrate buffer provided the best
results regarding recovery and peak height. The results for glycine buffers were comparable with
citrate, but the peaks are flatter. Acetate buffer gave the worst results, although it should be noted
that a smaller pH range was tested. The same trend can be observed for all three buffers: the lower
the pH value, the higher the recovery and the peak height. The salt concentration, on the other hand,
had only a minor influence. These observed trends correspond to the results of Mazzer et al. [25]
and Müller and Vajda. However, they contradict the high influence of the salt content described by
Gangnon et al. [30] and Bickel et al., at least in the ranges tested here.
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Figure 2. hro atography (left), aggregation and stability (right) results of the oE screening
experi ents ith three elution buffers (a): citrate buffer p 2.5–4, 0–0.5 a l; (b): glycine buffer
p 2.5–4, 0–0.5 aCl; (c): acetate buffer p 3.5–4, 0–0.5 NaCl). ggregation and stability ere
easured after one day at 4 ◦C. Citrate buffer showed the best performance during chromatography runs
as peaks were high and sharp (R = Recovery). The worst runs are marked with arrows. The aggregation
was low for acetate buffer and increased at low pH and with salt (citrate and glycine buffer). The highest
aggregation was measured with glycine buffer and is marked with an arrow. Stability experiments
showed a clear trend: with increasing pH, the stability increases for citrate and glycine buffer. The models
are shown with a surface diagram and experimental data was added.
In the stability tests (Figure 2, surface diagram) citrate and glycine buffer provided comparable
results regarding the amount of intact monoclonal antibody. The effect was opposite to the
chromatography results: the higher the pH value, the higher the proportion of intact antibody.
The salt concentration had hardly any influence here but can have a non-linear effect depending on the
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buffer used, in the investigated range of 0–0.5 M NaCl. For the acetate buffer, the results showed no
influence of pH and salt in the tested range.
In addition to chromatographic performance and the amount of intact antibody after incubation
in elution buffer, aggregate formation was investigated. Figure 2 shows the results after incubation
for 1 d at 4 ◦C. The greatest aggregation effects can be seen with the glycine buffer at low pH
and high salt concentration. Similar tendencies were observed for citrate buffers, however less
aggregates were formed. The aggregate formation for acetate in the pH range was also comparable
to the other buffers. Singla et al. [34] also compared these three buffer species at a fixed pH of 3.0.
Their results showed that at pH 3.0 citrate buffer induced the highest aggregate formation. In this
work, the NaCl concentration was higher and up to 0.5 M NaCl compared to the 0.1 M NaCl used
by Singla et al. This corresponds to the previously described order of aggregate formation that pH
and salt concentration have a higher influence than the buffer species. However, here acetate and
citrate buffer gave better results in regard to aggregation than glycine. Considering that temperature
also has a major effect on aggregation, it was measured after one week at −20 ◦C (freezing–thawing).
Glycine aggregation increased by 30% and the acetate and citrate buffer was increased by 100%.
Taking into account the previous results, the citrate buffer was selected for further optimization.
The citrate buffer provided the best results for chromatography with low aggregate formation and
stable antibody in the experimental area. As storing at low pH values is not usual, the aggregation
after one week is important but is not performed in a bioprocess.
3.1.2. Optimization of Citrate Buffer
To optimize the citrate buffer, the test range was limited to pH 3–3.8 and 0–0.2 M NaCl
(see Appendix A, Figure A2). Eleven experiments (see Table 2) were carried out according to a DoE
experiment plan. Chromatography runs were performed according to the experimental plan (Figure 3a).
For the stability experiments the incubation time was set to 60 min to imitate virus inactivation conditions.
For the chromatography experiments, the same tendencies were observed as in screening: the lower
the pH value, the higher the recovery and the peak height. Almost exclusively the pH-value influences
the performance. However, a contrary effect can again be seen in the stability results measured with
SEC-HPLC and Tycho NT.6 (see Appendix A, Figure A3). A low concentration of salt had a positive
effect on the stability and prevents aggregation. Therefore, pH 3.5 and 0.15 M NaCl were chosen for
the purification and the optimization and robustness were checked (Figure 3b). Under the selected
conditions, the recovery of the monoclonal antibody after the capture step was >95%. After purification
with the membrane adsorber Sartobind® Protein A 2 mL, the sample contained 0.26% aggregates,
which is comparable to the results of Müller and Vajda [32]. Taking into account the results after freezing
and thawing for one week, the aggregate content might further increase, therefore, immediate buffer
exchange is mandatory. These low values could be due to the experimental set up, which considers not
only the pH but also the salt (NaCl) concentration. Further, the use of membrane adsorbers leads to
decreased cycle times.
3.2. Continuous Membrane Purification of the Monoclonal Antibody
Continuous membrane chromatography was used to increase the productivity of the purification
step further with the optimized method from Section 3.1.2. The continuous chromatography method is
based on the principle of periodic counter-current chromatography (PCCC), which is controlled by
the UV signal of the membrane adsorber outlet. Therefore, the feed was diluted 1:3 to be in the linear
measuring range (A280 < ~1.5 AU) with a mAb concentration of 0.6 g/L.
3.2.1. Double Breakthrough Curve
In PCCC, up to two membrane adsorbers (MA) are loaded in series to capture the product
breakthrough of the first MA on the second MA. The UV signal of the breakthrough curve serves as
the dynamic control strategy for automation. This mode of operation allows loading of the MA close
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to the static binding capacity (available capacity of the MA in equilibrium) and thus results in a higher
capacity utilization of the MA. To design the process, different breakthrough curves were recorded with
the 4MA-PCCC (see Figure 4) to find the optimal feed rate and to determine the switching conditions
for the dynamic process control with the UV signal. The feed rate of 1.5 mL/min was found to be
suitable because the time for loading was equal to the time for regeneration, which is a criterion for
PCCC [55].
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The switching conditions were calculated as follows:
SC1 = 10%; ∆UV + UVimp = 1.28 AU (1)
SC2 = 70%; ∆UV + UVimp = 1.43 AU (2)
where ∆UV is the difference between the UV signal of the feed (UVmax) and the UV signal of the
impurity (here UVimp).
Membranes 2019, 9, x FOR PEER REVIEW 9 of 15 
 
3.2. Continuous Membrane Purification of the Monoclonal Antibody 
Continuous membrane chromatography was used to increase the productivity of the 
purification step further with the optimized method from Section 3.1.2. The continuous 
chromatography method is based on the principle of periodic counter-current chromatography 
(PCCC), which is controlled by the UV signal of the membrane adsorber outlet. Therefore, the feed 
was diluted 1:3 to be in the linear measuring range ( 280 < ~1.5 AU) with a mAb concentration of 0.6 
g/L. 
3.2.1. Double Breakthrough Curve 
In PCCC, up to two membrane adsorbers (MA) are loaded in series to capture the product 
breakthrough of the first MA on the second MA. The UV signal of the breakthrough curve serves as 
the dynamic control strategy for automation. This mode of operation allows loading of the MA close 
to the static binding capacity (available capacity of the MA in equilibrium) and thus results in a higher 
capacity utilization of the MA. To design the p ocess, different breakthro gh curves were recorded 
with the 4MA-PCCC (see Figure 4) to find the optimal feed rate and to determi e the switching 
conditions for the dynamic process control with the UV signal. The feed rate of 1.5 mL/min was found 
to be suitable because the time for loading was equal to the time for regeneration, which is a criterion 
for PCCC [55].  
The switching conditions were calculated as follows: 
SC1 = 10%; ∆UV + UVimp = 1.28  (1)
SC2 = 70%; ∆UV + UVimp = 1.43 AU (2)
here  is the ifference bet een the  signal of the fee  ( x) and the  signal of the 
i rity ( ere i p). 
 
Figure 4. Determination of a suitable flow rate for loading of the Sartobind® Protein A membrane 
adsorber for periodic counter-current chromatography (PCCC) operation. By increasing the flow rate, 
the double breakthrough curve got steeper. 1.5 mL/min was chosen as suitable flow rate. 
3.2.2. PCCC Application 
The continuous run was performed with 160 mL feed containing 0.6 g/L mAb. The 
chromatogram can be seen in Figure 5. Two cycles are shown, which were performed in 2 h. The 
double breakthrough curves can be seen whereas the mAb elution is marked with arrows. The elution 
peaks depict concentrations between 2.5 and 5 g/L (see Appendix A, Figure A1). Due to the dynamic 
process control, each membrane adsorber was loaded until it was saturated. Slight differences occur 
due to the system setup. At the end of the loading a small peak can be seen, which was captured on 
a further membrane adsorber (interconnected wash [52,53]). A constant performance of the MA can 
0 4 8 12 16 20
0.0
0.4
0.8
1.2
1.6
A 2
80
 [A
U]
Time [min]
 2 mL/min  5 mL/min
UVimp= 1.25 AU
UVmax= 1.50 AU
SC1 = 1.28 AU
SC2 = 1.43 AU
 1.5 mL/min
Figure 4. eter ination of a suitable flo rate for loading of the Sartobind® Protein e brane
adsorber for periodic counter-current chro atography (P ) operation. By increasing the flo rate,
the double breakthrough curve got steeper. 1.5 L/ in as chosen as suitable flo rate.
Membranes 2019, 9, 159 10 of 15
3.2.2. PCCC Application
The continuous run was performed with 160 mL feed containing 0.6 g/L mAb. The chromatogram can
be seen in Figure 5. Two cycles are shown, which were performed in 2 h. The double breakthrough curves
can be seen whereas the mAb elution is marked with arrows. The elution peaks depict concentrations
between 2.5 and 5 g/L (see Appendix A, Figure A1). Due to the dynamic process control, each membrane
adsorber was loaded until it was saturated. Slight differences occur due to the system setup. At the end of
the loading a small peak can be seen, which was captured on a further membrane adsorber (interconnected
wash [52,53]). A constant performance of the MA can be observed in the process, but a trend (MA1 to MA4)
can be seen in each cycle. The elution peaks decrease because the self-built system has back suction from
buffer B. In this system, the very complex circuit was realized with 37 valves and this resulted in a high dead
volume, which causes the back suction. Nevertheless, the recovery after the purification was higher than
90% and only 600 mL buffer was consumed. Compared to the batch process, the capacity utilization of the
MA was increased by 20% due to the loading principle of PCCC. Further, the optimized chromatography
conditions showed a significant improvement in the PCCC compared to the non-optimized conditions
(see Appendix A, Figure A3).
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4. Discussion
This study presents the optimization of the critical Protein A purification step in monoclonal
antibody downstream processing with a focus on the elution. Up until now, downstream processing
has been a bottleneck in the production process, since high product titers must be processed in
compliance with legal requirements. The Protein A step is critical because a low pH is used for
product elution, which can lead to aggregation and thus to problems in quality, quantity, further
processing and above all, in drug safety. It is therefore vital to optimize the downstream process. In this
study, the elution was optimized with various buffers and the application of membrane adsorbers
(Sartobind® Protein A 2 mL) as an alternative to conventional column chromatography. Although the
capacities were still lower than in column chromatography, the throughputs were significantly higher
and the residence times were shorter. This is particularly interesting for mAb elution. For the IgG1
mAb, tested in this work, 0.1 M citrate buffer pH 3.5 + 0.15 M NaCl provided the best results in
terms of MA chromatography performance, product stability and aggregation (tested with SEC-HPLC
and Tycho NT.6). Furthermore, the development time of the process could be significantly reduced
with membrane adsorbers. The optimized chromatography method was successfully transferred to
a continuous chromatography system operated with four membrane adsorbers (4MA-PCCC).
The PCCC principle is very suitable for the purification of mAbs because the product concentration
is quite high compared to other products [51,56]. The control via the UV signal using the switching
conditions could be easily implemented. Due to increasing product titers > 5 g/L [57], this will improve
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even further. This is particularly useful in relation to the process analytical technology (PAT) initiative
defined by the FDA [58]. The process can be monitored directly and the performance is directly visible.
The process can be stopped before the performance decreases and the product quality no longer meets
the legal requirements. This could increase the economics of the DSP, since better utilization of the MA
used would increase productivity.
In conclusion, this work shows the structured optimization of a monoclonal antibody
purification step. It is very important to control the quality of the antibody throughout the entire
optimization process in order to ensure high product quality and to identify the critical steps. By using
DoE, the number of experiments could be reduced and thus the optimization was very fast. The use of
membrane adsorbers has the advantage that the process is easily scalable and the disposable MA can
be disposed of after use. Furthermore, the transfer of the batch to continuous operation mode was
described, and this is very relevant to current developments in the biotechnological industry.
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Figure A1. Calibration data of the mAb at the 4MA-PCCC system with a 2 mm flow through cuvette. 
Purified mAb solution was measured in the UV cuvettes. Small deviations occurred due to the use of 
optical fibers. Limit of detection (LOD) and limit of quantification (LOQ) were determined 
individually and the averages were calculated: LOD = 0.009 g/L and LOQ = 0.029 g/L. 
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